

**REMARKS**

The foregoing amendments are made to insert the required SEQ ID NO identifiers associated with various listed sequences, as well as to correct certain disclosure in Table 1 and Figure 6b. Specifically, the specification shows certain oligonucleotide sequences as containing thymidine (t) nucleotides and then states: "In addition it is to be noted that any of the "t" above are actually "u" given the fact that the above antisense oligonucleotides are GeneBlocs, i. e. third generation antisense oligonucleotides." Applicants have therefore amended the specification to replace the relevant "t" nucleotides with corresponding uracil ("u") residues. Support for said corrections may be found the paragraph directly following Table 1, as well as in the figure description for Figure 6. Formal drawings correcting said changes to Figure 6 will be presented upon allowance of the application.

Applicants believe that the present application is now in condition for allowance. Favorable reconsideration of the application as amended is respectfully requested.

Should additional fees be necessary in connection with the filing of this paper, or if a Petition for Extension of Time is required for timely acceptance of same, the Commissioner is hereby authorized to charge Deposit Account No 08-1641 for any such fees; and applicants hereby petition for any needed extension of time.

The Examiner is invited to contact the undersigned by telephone if it is felt that a telephone interview would advance the prosecution of the present application.

Respectfully submitted,

Date Mar 13, 2006



HELLER EHRMAN, L.L.P.  
1717 Rhode Island Ave., NW  
Washington, DC 20036-3001  
Telephone: 202-912-2000  
Facsimile: 202-912-2020

Paul M. Booth  
Registration No. 40,244  
Attorney for Applicant  
  
Customer No. 26633

5/11

\*Fig. 6 Met-WP




Fig. 6